KDR and prostate cancer: Specifically, miR-221 is reported to regulate KDR (Kinase Insert Domain Receptor)—also known as VEGFR2 (Vascular Endothelial Growth Factor Receptor 2)—in ccRCC [46] and prostate cancer [47], thereby regulating the sensitivity towards sunitinib.